What is Micro Interventional Devices?
Micro Interventional Devices (MID) operates at the intersection of medical technology and cardiovascular innovation. The company specializes in the design, manufacturing, and commercialization of sophisticated catheter-based systems engineered to address the complexities of structural heart disease. By providing a viable, less invasive alternative to traditional open-heart surgery, MID is effectively disrupting the standard of care for patients requiring tricuspid valve intervention.
The firm's market position is defined by its commitment to improving clinical outcomes, reducing operative duration, and enhancing the overall ease of use for surgical teams. Through its focus on Transcatheter Cardiac Repair, MID is not only addressing a significant unmet medical need but is also establishing itself as a key player in the global cardiovascular device market. Their strategic focus on innovation ensures that they remain at the forefront of minimally invasive cardiac care.
How much funding has Micro Interventional Devices raised?
Micro Interventional Devices has raised a total of $24.3M across 6 funding rounds:
Private Equity
$250K
Debt
$100K
Series B
$3.5M
Series D
$20M
Debt
$150K
Debt
$262K
Private Equity (2012): $250K with participation from The Life Sciences Greenhouse of Central Pennsylvania
Debt (2012): $100K led by Ben Franklin Technology Partners of Northeastern Pennsylvania
Series B (2013): $3.5M supported by Originate Ventures and Battelle Ventures, LP
Series D (2019): $20M featuring OSCOR
Debt (2020): $150K backed by PPP
Debt (2021): $262K with participation from PPP
Key Investors in Micro Interventional Devices
Originate Ventures
An early-stage venture capital firm based in Bethlehem, PA, focused on investing in emerging companies primarily located in Pennsylvania and New Jersey, providing both capital and entrepreneurial guidance.
Battelle Ventures, LP
A venture firm managing significant capital to accelerate early-stage technology companies, leveraging deep relationships with national laboratories and university tech transfer offices.
The Life Sciences Greenhouse of Central Pennsylvania
An evergreen venture fund dedicated to advancing the life sciences ecosystem in Pennsylvania by providing early-stage financing and operational expertise to innovative healthcare companies.
What's next for Micro Interventional Devices?
With the recent infusion of capital, Micro Interventional Devices is poised to scale its operational capabilities and deepen its penetration into the global healthcare market. The strategic roadmap likely involves accelerating the clinical adoption of the MIA-T system and potentially expanding the product pipeline to address broader structural heart pathologies. By maintaining a focus on operational excellence and clinical efficacy, the company is well-equipped to navigate the regulatory and competitive landscapes of the medical device industry.
Future growth will likely be driven by continued investment in research and development, alongside strategic partnerships that enhance the distribution and accessibility of their TCR technologies. As the company matures, the focus will shift toward long-term value creation for stakeholders and the sustained improvement of patient quality of life through technological advancement.
